Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Neil Bodick, MD
Flexion Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Anaheim, California, United States
- Facility name not stated
El Cajon, California, United States
- Facility name not stated
North Hollywood, California, United States
- Facility name not stated
Duncansville, Pennsylvania, United States
- Facility name not stated
Mt. Pleasant, South Carolina, United States
- Facility name not stated
Knoxville, Tennessee, United States
- Facility name not stated
Dallas, Texas, United States
- Facility name not stated
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2016
- Primary completion
- 31 Oct 2016
- Completion
- 30 Nov 2016
- Last update posted
- 24 Jan 2024
- Registered enrollment
- 33
- Registry id
- NCT02762370
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.